Predictors of Disease Activity and Worsening in Relapsing-Remitting Multiple Sclerosis

Discussion Prospective data from a large clinical trial cohort show that younger MS patients with high BL relapses and MRI lesion burden have the highest risk of subsequent disease activity. Trial Registration Information Clinical trial registration number NCT00211887. CombiRx was registered at ClinicalTrials.gov (NCT00211887) on September 21, 2005. Study enrollment began in January 2005.

http://cp.neurology.org/cgi/content/short/12/4/e58?rss=1

Source: Neurology Clinical Practice - August 9, 2022 Category: Neurology Authors: Zhang, Y., Cofield, S., Cutter, G., Krieger, S., Wolinsky, J. S., Lublin, F. Tags: MRI, Prognosis, All Clinical trials, Multiple sclerosis Research Article Source Type: research